The Jazz Pharmaceuticals plc – (JAZZ) Earns Outperform Rating from Analysts at Royal Bank of Canada

The Jazz Pharmaceuticals plc – (JAZZ) Earns Outperform Rating from Analysts at Royal Bank of Canada

A number of other equities research analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of Jazz Pharmaceuticals plc – from a “hold” rating to a “sell” rating in a report on Tuesday, May 2nd. Janney Montgomery Scott raised shares of Jazz Pharmaceuticals plc – from a “neutral” rating to a “buy” rating and upped their target price for the company from $138.00 to $175.00 in a report on Thursday, April 6th. Vetr cut shares of Jazz Pharmaceuticals plc – from a “strong-buy” rating to a “buy” rating and set a $161.19 target price on the stock. in a report on Monday, March 27th. BMO Capital Markets reaffirmed a “top pick” rating and issued a $192.00 target price on shares of Jazz Pharmaceuticals plc – in a report on Wednesday, February 15th. Finally, Deutsche Bank AG set a $176.00 target price on shares of Jazz Pharmaceuticals plc – and gave the company a “buy” rating in a report on Thursday, April 6th. Three analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $182.30.

Research analysts at Royal Bank of Canada assumed coverage on shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) in a report released on Monday, May 15th. The firm set an “outperform” rating and a $210.00 price target on the specialty pharmaceutical company’s stock. Royal Bank of Canada’s target price suggests a potential upside of 41.33% from the stock’s current price.

Jazz Pharmaceuticals plc – (NASDAQ JAZZ) opened at 148.59 on Monday. Jazz Pharmaceuticals plc – has a 1-year low of $95.80 and a 1-year high of $163.75. The stock has a 50 day moving average price of $153.80 and a 200-day moving average price of $131.85. The company has a market capitalization of $8.92 billion, a price-to-earnings ratio of 22.45 and a beta of 1.22.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last issued its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $1.41 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.42 by $0.01. The firm had revenue of $376.10 million during the quarter, compared to the consensus estimate of $376.58 million. Jazz Pharmaceuticals plc – had a net margin of 24.81% and a return on equity of 30.50%. The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the previous year, the company posted $2.26 earnings per share. Equities analysts predict that Jazz Pharmaceuticals plc – will post $11.00 earnings per share for the current year. In other news, SVP Michael Patrick Miller sold 200 shares of the firm’s stock in a transaction that occurred on Wednesday, March 15th. The shares were sold at an average price of $137.89, for a total transaction of $27,578.00. Following the transaction, the senior vice president now directly owns 22,762 shares of the company’s stock, valued at $3,138,652.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Karen J. Wilson sold 11,458 shares of the firm’s stock in a transaction that occurred on Monday, April 10th. The stock was sold at an average price of $152.24, for a total transaction of $1,744,365.92. Following the transaction, the senior vice president now directly owns 27,158 shares in the company, valued at $4,134,533.92. The disclosure for this sale can be found here. Insiders have sold 54,333 shares of company stock worth $8,343,272 over the last ninety days. Insiders own 3.90% of the company’s stock.

Several hedge funds have recently bought and sold shares of JAZZ. Tamarack Advisers LP purchased a new stake in Jazz Pharmaceuticals plc – during the third quarter valued at about $12,082,000. Mitsubishi UFJ Trust & Banking Corp raised its stake in Jazz Pharmaceuticals plc – by 0.5% in the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 124,531 shares of the specialty pharmaceutical company’s stock valued at $15,128,000 after buying an additional 609 shares in the last quarter. Wells Fargo & Company MN raised its stake in Jazz Pharmaceuticals plc – by 17.2% in the third quarter. Wells Fargo & Company MN now owns 506,079 shares of the specialty pharmaceutical company’s stock valued at $61,478,000 after buying an additional 74,342 shares in the last quarter. Credit Agricole S A raised its stake in Jazz Pharmaceuticals plc – by 24.9% in the fourth quarter. Credit Agricole S A now owns 10,935 shares of the specialty pharmaceutical company’s stock valued at $1,193,000 after buying an additional 2,181 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. purchased a new stake in Jazz Pharmaceuticals plc – during the third quarter valued at about $30,370,000. Institutional investors and hedge funds own 88.56% of the company’s stock. About Jazz Pharmaceuticals plc –

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:JAZZ”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment